全文获取类型
收费全文 | 23289篇 |
免费 | 1519篇 |
国内免费 | 119篇 |
专业分类
耳鼻咽喉 | 211篇 |
儿科学 | 637篇 |
妇产科学 | 575篇 |
基础医学 | 3726篇 |
口腔科学 | 340篇 |
临床医学 | 1931篇 |
内科学 | 5564篇 |
皮肤病学 | 619篇 |
神经病学 | 2503篇 |
特种医学 | 601篇 |
外科学 | 2350篇 |
综合类 | 95篇 |
一般理论 | 12篇 |
预防医学 | 1708篇 |
眼科学 | 448篇 |
药学 | 1621篇 |
中国医学 | 55篇 |
肿瘤学 | 1931篇 |
出版年
2023年 | 263篇 |
2022年 | 216篇 |
2021年 | 801篇 |
2020年 | 505篇 |
2019年 | 784篇 |
2018年 | 827篇 |
2017年 | 635篇 |
2016年 | 715篇 |
2015年 | 789篇 |
2014年 | 1073篇 |
2013年 | 1256篇 |
2012年 | 1896篇 |
2011年 | 1990篇 |
2010年 | 1118篇 |
2009年 | 1021篇 |
2008年 | 1577篇 |
2007年 | 1609篇 |
2006年 | 1505篇 |
2005年 | 1409篇 |
2004年 | 1209篇 |
2003年 | 1134篇 |
2002年 | 979篇 |
2001年 | 132篇 |
2000年 | 91篇 |
1999年 | 139篇 |
1998年 | 129篇 |
1997年 | 112篇 |
1996年 | 75篇 |
1995年 | 88篇 |
1994年 | 68篇 |
1993年 | 63篇 |
1992年 | 50篇 |
1991年 | 43篇 |
1990年 | 36篇 |
1989年 | 39篇 |
1988年 | 32篇 |
1987年 | 29篇 |
1986年 | 43篇 |
1985年 | 30篇 |
1984年 | 21篇 |
1983年 | 20篇 |
1982年 | 21篇 |
1981年 | 24篇 |
1980年 | 24篇 |
1979年 | 15篇 |
1975年 | 18篇 |
1972年 | 15篇 |
1971年 | 16篇 |
1969年 | 14篇 |
1966年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 469 毫秒
1.
Rizzo Giuseppe Pietrolucci Maria Elena Capponi Alessandra Mappa Ilenia 《The international journal of cardiovascular imaging》2022,38(5):1017-1019
The International Journal of Cardiovascular Imaging - 相似文献
2.
3.
Mariángeles González Fernández Elena Villamañán Inmaculada Jiménez-Nácher Francisco Moreno Chamaida Plasencia Francisco Gayá Alicia Herrero Alejandro Balsa 《Reumatología clinica》2021,17(6):335-342
ObjectiveTo assess the evolution of cost per patient/year and the cost per patient/year/drug in patients with rheumatoid arthritis (RA) receiving biological treatments. To analyze and quantify the factors influencing this evolution, such as the optimization of the biological drugs, the use of biosimilars, and official discounts and discounts obtained after negotiated procedures. In addition, to assess specific clinical parameters of disease activity in these patients.MethodsRetrospective, observational study conducted in a Spanish tertiary hospital. Adult patients diagnosed with RA under treatment from 2009 to 2017 were included.Results320, 270 and 389 patients were included in 2009, 2013 and 2017, respectively. The patient/year cost decreased from 10,789€ in 2009, 7491€ in 2013 to 7116€ in 2017. In 2017, due to the established competition, discounts of 14% and 29.5% were achieved on etanercept and its biosimilar; 11.5%, 17.8%, 17.9%, 17.3% on adalimumab, certolizumab, golimumab and tocilizumab IV respectively, and 24.6% and 43.1% on infliximab and its biosimilar. The percentage of patients optimized in 2017 was 35.2%. The annual saving in 2017 was 1,288,535€ (830,000€ due to dose optimization and/or administration regimens, 249,666€ corresponding to 7.5% of the official discount and 208,868€ after negotiated procedures).ConclusionThe annual cost per patient in RA decreased considerably due to different factors, such as discounts on the purchase of drugs due to official discounts and negotiated procedures, together with the optimization of therapies, the latter being the factor that contributed most to this decrease. 相似文献
4.
5.
Jeff Unger MD Dale C. Allison MD Margit Kaltoft MD Kavitha Lakkole MBA Jayant K. Panda MD Chethana Ramesh MSc Mehmet Sargin MD Elena Smolyarchuk MD Melissa Twine BS Benjamin Wolthers MD Gizem Yarimbas MSc Marouan Zoghbi MD the LIRA-PRIME investigators 《Diabetes, obesity & metabolism》2022,24(2):204-211
6.
Cheryl L. Rock PhD RD Cynthia A. Thomson PhD RD Kristen R. Sullivan MS MPH Carol L. Howe MD MLS Lawrence H. Kushi ScD Bette J. Caan DrPH Marian L. Neuhouser PhD RD Elisa V. Bandera MD PhD Ying Wang PhD Kimberly Robien PhD RD Karen M. Basen-Engquist PhD MPH Justin C. Brown PhD Kerry S. Courneya PhD Tracy E. Crane PhD RDN David O. Garcia PhD FACSM Barbara L. Grant MS RDN CSO FAND Kathryn K. Hamilton MA RDN CSO CDN FAND Sheri J. Hartman PhD Stacey A. Kenfield ScD Maria Elena Martinez PhD Jeffrey A. Meyerhardt MD MPH Larissa Nekhlyudov MD MPH Linda Overholser MD Alpa V. Patel PhD Bernardine M. Pinto PhD Mary E. Platek PhD RD CDN Erika Rees-Punia PhD MPH Colleen K. Spees PhD MEd RD LD FAND Susan M. Gapstur PhD Marjorie L. McCullough ScD RD 《CA: a cancer journal for clinicians》2022,72(3):230-262
The overall 5-year relative survival rate for all cancers combined is now 68%, and there are over 16.9 million survivors in the United States. Evidence from laboratory and observational studies suggests that factors such as diet, physical activity, and obesity may affect risk for recurrence and overall survival after a cancer diagnosis. The purpose of this American Cancer Society guideline is to provide evidence-based, cancer-specific recommendations for anthropometric parameters, physical activity, diet, and alcohol intake for reducing recurrence and cancer-specific and overall mortality. The audiences for this guideline are health care providers caring for cancer survivors as well as cancer survivors and their families. The guideline is intended to serve as a resource for informing American Cancer Society programs, health policy, and the media. Sources of evidence that form the basis of this guideline are systematic literature reviews, meta-analyses, pooled analyses of cohort studies, and large randomized clinical trials published since 2012. Recommendations for nutrition and physical activity during cancer treatment, informed by current practice, large cancer care organizations, and reviews of other expert bodies, are also presented. To provide additional context for the guidelines, the authors also include information on the relationship between health-related behaviors and comorbidities, long-term sequelae and patient-reported outcomes, and health disparities, with attention to enabling survivors' ability to adhere to recommendations. Approaches to meet survivors' needs are addressed as well as clinical care coordination and resources for nutrition and physical activity counseling after a cancer diagnosis. 相似文献
7.
Sibylle M. Winter Katja Dittrich Peggy Dörr Judith Overfeld Imke Moebus Elena Murray Gergana Karaboycheva Christian Zimmermann Andrea Knop Manuel Voelkle Sonja Entringer Claudia Buss John-Dylan Haynes Elisabeth B. Binder Christine Heim 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(9):1027-1045
8.
9.
Norito Katoh Hidehisa Saeki Yoko Kataoka Takafumi Etoh Satoshi Teramukai Hiroki Takagi Yuki Tajima Marius Ardeleanu Elena Rizova Kazuhiko Arima 《The Journal of dermatology》2019,46(4):290-300
Moderate to severe atopic dermatitis (AD) has a high disease burden and a significant effect on quality of life. Observational studies are necessary to determine the patient disease burden and long‐term disease control in the Japanese population. ADDRESS‐J is a non‐interventional, observational registry of adult Japanese patients with moderate to severe AD. Herein, we report baseline data from the ADDRESS‐J study describing disease characteristics and current treatment practices. At baseline, 300 adult AD patients with Investigator's Global Assessment (IGA) scores (range, 0–4) of 3 (moderate) or 4 (severe) whose treatments for AD were intensified, were assessed for clinical and patient‐reported outcomes and current AD treatments. The registry patients’ median age was 34.0 years; 60.7% were male and 71.7% had had AD for more than 20 years. At baseline, 220 study patients had an IGA score of 3 and 80 had an IGA score of 4. The median Eczema Area and Severity Index score was 21.7 (range, 0–72), the median body surface area involvement was 46.25%, and the median pruritus numerical rating scale score was 7.0 (range, 0–10); for each of these measures, higher scores represent greater severity. Most registry patients (86.7%) had recently used topical corticosteroids or topical calcineurin inhibitors as treatment for AD. This registry cohort represents a population of Japanese patients with moderate to severe AD and provides an important resource for characterizing the disease burden and evaluating the safety and effectiveness of various AD treatments. 相似文献